<DOC>
	<DOCNO>NCT01180049</DOCNO>
	<brief_summary>This study compare effectiveness safety two different dos temsirolimus ( Torisel ) .</brief_summary>
	<brief_title>Comparison Of 2 Doses Of Temsirolimus ( Torisel ) In Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Have confirm mantle cell lymphoma diagnosis . Have measurable disease . Have receive least 2 prior treatment , may include stem cell transplant . Have adequate organ bone marrow function . There criteriaplease discus doctor . Had prior treatment temsirolimus mTOR inhibitor . Had allogeneic stem cell transplant within last 6 month immunosuppressive therapy . Has active untreated brain central nervous system metastasis . There criteriaplease discus doctor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>non-Hodgkin lymphoma ( NHL )</keyword>
	<keyword>temsirolimus</keyword>
</DOC>